Every story in this section, newest first — page 331 of 373.
Concentrix Corporation (NASDAQ:CNXC) reported fourth-quarter and full-year 2025 results that beat its own revenue targets, even as a massive non-cash impairment charge forced the company into a GAAP operating loss.
NeuroPace (NASDAQ:NPCE) crossed a major financial threshold in 2025, reporting preliminary full-year revenue of approximately $100 million as its brain-responsive neurostimulation technology gains traction as a standard of care for drug-resistant epilepsy.
Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.
JPMorgan Chase & Co. (NYSE:JPM) kicked off the 2026 earnings season on Tuesday with a complex set of results that highlighted a growing divide between its "Main Street" lending and "Wall Street" trading arms.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.
Sight Sciences (NASDAQ:SGHT), a leader in interventional eyecare technologies, released preliminary fourth-quarter 2025 results on Jan. 13, showing a return to growth driven by its interventional dry eye business.
Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.
Armata Pharmaceuticals (NYSE:ARMP) is poised to become the first company to advance a bacteriophage candidate into a Phase 3 clinical trial, following a positive End-of-Phase 2 (EOP2) response from the U.S. Food and Drug Administration (FDA).
AerCap Holdings N.V. (NYSE:AER), the world’s largest aircraft lessor, has reached a significant agreement with Virgin Atlantic to finance six new Airbus A330-900 aircraft.
Cardinal Health (NYSE:CAH) raised its fiscal year 2026 earnings outlook Tuesday, citing rapid acceleration in its specialty pharmaceutical business and a successful navigating of federal drug pricing changes.
Lazard (NYSE:LAZ) reported that its preliminary assets under management (AUM) reached approximately $254.3 billion as of December 31, 2025.
nLIGHT (NASDAQ:LASR), a prominent manufacturer of high-power semiconductor and fiber lasers, announced preliminary fourth-quarter results for 2025 that exceeded its previous financial targets.
Delta Air Lines (NYSE:DAL) reported robust financial results for the fourth quarter and full year 2025, overcoming a year of fluctuating travel demand to deliver record cash flow and solid profitability.
Black Rifle Coffee Company (NYSE:BRCC) confirmed today that it expects to meet its previously issued financial targets for the 2025 fiscal year, despite a minor gross margin compression caused by a product formulation change.
Kestra Medical Technologies (NASDAQ:KMTS) has announced a strategic collaboration and exclusive co-development agreement with Biobeat Technologies to integrate advanced hemodynamic monitoring into its cardiac recovery platform.
Unity Bancorp (NASDAQ:UNTY), the parent company of Unity Bank, reported a record-breaking fiscal year 2025, characterized by robust loan growth and industry-leading profitability metrics.
GDS Holdings Limited (NASDAQ:GDS), China’s largest carrier-neutral data center operator, has agreed to sell a portion of its stake in its international arm, DayOne, back to the subsidiary for $385 million.
Aclarion (NASDAQ:ACON), a commercial-stage healthcare technology company, has closed a $10.4 million common-stock-only financing, significantly bolstering its balance sheet as it seeks to transform the diagnosis of chronic low back pain.
TryHard Holdings (NASDAQ:THH), a prominent lifestyle entertainment operator based in Japan, has entered into a binding collaboration agreement with Carnegie Hill Capital Partners to launch a new investment vehicle focused on the global entertainment sector.
AbbVie (NYSE:ABBV) has entered into a voluntary three-year agreement with the Trump administration, pledging a massive $100 billion investment in U.S.-based research, development, and manufacturing over the next decade.
Visionary Holdings (NASDAQ:GV) shares are under pressure after the company’s 2025 annual report revealed a significant revenue contraction and mounting liquidity concerns.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
HIVE Digital Technologies (NASDAQ:HIVE) announced Tuesday a strategic joint venture to launch the BUZZ AI cloud platform in Asunción, marking one of Paraguay’s first purpose-built facilities for artificial intelligence and high-performance computing (HPC).
California Governor Gavin Newsom says a proposed wealth tax could damage the state’s economy and drive billionaires away.
